Banner Alzheimers Institute

Phoenix, Arizona 85020

10 studies enrolling now · 87 studies all time

What they study most

Alzheimer Disease, Alzheimer Disease (AD), Alzheimer Disease Due to P. Gingivalis, Alzheimer's Disease, Alzheimer's Disease (AD), Alzheimers Disease, Alzheimer´s Disease, Amnestic Mild Cognitive Impairment, Apathy, Brain Diseases, Central Nervous System Diseases, Chronic Traumatic Encephalopathy

Studies at this site

• Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease — Recruiting now
• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Recruiting now
• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) — Recruiting now
• Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies — Recruiting now
• A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). — Recruiting now
• A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease — Recruiting now
• Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies — Recruiting now
• A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease — Running, not enrolling
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) — Completed
• Alzheimer's Disease Neuroimaging Initiative 4 — Enrolling by invitation
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) — Completed
• A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease — Completed
• AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid — Running, not enrolling
• Study of AV-1959D, an Amyloid Beta Vaccine — Running, not enrolling
• A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) — Completed
• Alzheimer's Disease Neuroimaging Initiative 3 — Completed
• A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease — Stopped early
• A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) — Running, not enrolling
• Evaluation of a Finger Prick Collection Method for Measuring Alzheimer's Disease Blood Biomarkers — Completed
• GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) Genotype — Enrolling by invitation
• Draw-10: A Weekly Blood Draw Study to Understand the Biological Variability of Plasma pTau-217 — Completed
• A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Running, not enrolling
• A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease — Completed
• Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease — Stopped early
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• APOE in the Predisposition to, Protection From, and Prevention of Alzheimer's Disease — Enrolling by invitation
• A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT) — Completed
• A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) — Stopped early
• 18F-AV-1451 High Resolution Autopsy Study — Completed
• Alzheimer's Plasma Extension — Running, not enrolling
• Open-label Extension for Phase 3 Clinical Trials of Simufilam — Stopped early
• A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease — Stopped early
• A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 — Stopped early
• Alzheimer's Disease Neuroimaging Initiative 2 — Completed
• The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF) — Completed
• Arizona Alzheimer's Disease Research Center (ADRC) — Status unconfirmed
• TRC-PAD Program: In-Clinic Trial-Ready Cohort — Completed
• Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease — Completed
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD) — Stopped early
• Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) — Stopped early
• Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study — Completed
• 18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN Study — Completed
• Apathy in Dementia Methylphenidate Trial 2 — Completed
• SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study — Completed
• GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease — Completed
• A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease — Paused
• Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease — Stopped early
• A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease — Completed
• A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease — Completed
• A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities — Stopped early